India · Delayed Price · Currency is INR Vivimed Labs Statistics
Total Valuation
Vivimed Labs has a market cap or net worth of INR 460.17 million. The enterprise value is 4.29 billion.
| Market Cap | 460.17M |
| Enterprise Value | 4.29B |
Important Dates
The next estimated earnings date is Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivimed Labs has 82.91 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 82.91M |
| Shares Outstanding | 82.91M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 11.57% |
| Owned by Institutions (%) | 6.94% |
| Float | 64.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| PB Ratio | -0.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.28 |
| EV / Sales | 4.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.95 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -8.90% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 1.44% |
| Revenue Per Employee | 1.51M |
| Profits Per Employee | -596,399 |
| Employee Count | 586 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vivimed Labs has paid 1.13 million in taxes.
| Income Tax | 1.13M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.50 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7.37 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 23.91 |
| Average Volume (20 Days) | 183,570 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vivimed Labs had revenue of INR 883.92 million and -349.49 million in losses. Loss per share was -4.21.
| Revenue | 883.92M |
| Gross Profit | 483.67M |
| Operating Income | -298.22M |
| Pretax Income | -348.36M |
| Net Income | -349.49M |
| EBITDA | -93.86M |
| EBIT | -298.22M |
| Loss Per Share | -4.21 |
Balance Sheet
The company has 10.12 million in cash and 3.84 billion in debt, with a net cash position of -3.83 billion or -46.20 per share.
| Cash & Cash Equivalents | 10.12M |
| Total Debt | 3.84B |
| Net Cash | -3.83B |
| Net Cash Per Share | -46.20 |
| Equity (Book Value) | -479.63M |
| Book Value Per Share | -5.78 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 204.36M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 54.72%, with operating and profit margins of -33.74% and -39.54%.
| Gross Margin | 54.72% |
| Operating Margin | -33.74% |
| Pretax Margin | -39.41% |
| Profit Margin | -39.54% |
| EBITDA Margin | -10.62% |
| EBIT Margin | -33.74% |
| FCF Margin | n/a |
Dividends & Yields
Vivimed Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.03% |
| Earnings Yield | -75.95% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 6, 2016. It was a forward split with a ratio of 5.
| Last Split Date | Apr 6, 2016 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |